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Safety of Paclitaxel-Coated Balloon
Angioplasty for Femoropopliteal
Peripheral Artery Disease
Kenneth Ouriel, MD,a Mark A. Adelman, MD,a Kenneth Rosenﬁeld, MD,b Dierk Scheinert, MD,c
Marianne Brodmann, MD,d Constantino Peña, MD,e Patrick Geraghty, MD,f Arthur Lee, MD,g Roseann White, MA,a
Daniel G. Clair, MDh

ABSTRACT
OBJECTIVES The aim of this study was to assess safety outcomes of femoropopliteal drug-coated balloon (DCB)
angioplasty using patient-level data from the Lutonix clinical program.
BACKGROUND A recent systematic review and meta-analysis of heterogenous trials and summary-level data identiﬁed
increased long-term mortality in patients treated with paclitaxel-coated balloons and stents.
METHODS We evaluated DCB angioplasty (n ¼ 1,093) and uncoated balloon angioplasty (percutaneous transluminal
angioplasty [PTA]) (n ¼ 250) outcomes in LEVANT 1 (The Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropopliteal Restenosis), LEVANT 2 (Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment
of Femoropopliteal Arteries), and the LEVANT Japan Clinical Trial. Hazard ratios (HRs) were calculated with Cox proportional hazards modeling.
RESULTS There were no signiﬁcant differences in mortality rates between DCB angioplasty and PTA. The 5-year HR was
1.01 (95% conﬁdence interval [CI]: 0.68 to 1.52) in the aggregated LEVANT trials. The 2-year HR after DCB angioplasty
was 0.99 (95% CI: 0.25 to 3.95) in LEVANT 1, 1.40 (95% CI: 0.62 to 3.14) in LEVANT 2, and 0.32 (95% CI: 0.05 to 1.92)
in the LEVANT Japan Clinical Trial. The 5-year HR was 1.60 (95% CI: 0.94 to 2.72) in LEVANT 2. Adverse events and
causes of death were balanced, without clustering between DCB angioplasty and PTA. Patients who underwent paclitaxel
or nonpaclitaxel reinterventions had higher survival rates than those who did not undergo reinterventions. Baseline
covariates predicting mortality included, among others, age (HR: 1.03 per year; p < 0.0001), prior treatment of target
lesion (HR: 1.67; p ¼ 0.022), arrhythmia (HR: 1.65; p ¼ 0.031), and diabetes (HR: 1.18; p ¼ 0.047), without differences
between the 2 arms. No dose-response relationship was identiﬁed when adjusted for key predictors of mortality.
CONCLUSIONS Analyses of patient-level data identiﬁed no mortality differences between DCB angioplasty and PTA.
Furthermore, the lack of dose-response relationships or clustering of causes of death argues against a causal relationship
between paclitaxel and mortality. (LEVANT 1, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis [LEVANT 1], NCT00930813; Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the
Treatment of Femoropopliteal Arteries [LEVANT 2], NCT01412541; LEVANT 2 Continued Access Registry, NCT01628159;
LEVANT Japan Clinical Trial, NCT01816412) (J Am Coll Cardiol Intv 2019;12:2515–24) © 2019 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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L

ABBREVIATIONS

artery

femoropopliteal clinical program, LEVANT 1 (The

disease (PAD) is an increasingly prev-

Lutonix Paclitaxel-Coated Balloon for the Prevention

alent global health concern, associ-

of Femoropopliteal Restenosis), LEVANT 2 (Moxy

ated with a 3- to 5-fold increase in mortality

Drug Coated Balloon vs. Standard Balloon Angio-

risk over that of the general population

plasty for the Treatment of Femoropopliteal Arteries),

(1,2). Although endovascular or open surgical

and the LEVANT Japan Clinical Trial, and the single-

HR = hazard ratio

revascularization is recommended for pa-

arm continued-access arm of the LEVANT 2 trial

PAD = peripheral artery

tients with symptomatic femoropopliteal

(Table 1). These studies are a subset of the 3,095 pa-

PAD, there remains no consensus on the

tients treated in the Lutonix global femoropopliteal

optimal strategy for this patient population (3).

clinical program that enrolled 2,845 patients (91.9%)

Traditional therapies for femoral popliteal

treated with the Lutonix DCB and 250 (8.1%) with

PAD include uncoated balloon angioplasty

uncoated PTA. The primary analysis focused on the

(percutaneous transluminal angioplasty [PTA]), stent

LEVANT 2 randomized trial, the largest of the ran-

placement, and atherectomy (4). In this landscape,

domized trials with the longest follow-up duration,

drug-eluting stents (DES) and drug-coated balloons

spanning 5 years. The LEVANT 1, LEVANT Japan

(DCBs) were developed, using antiproliferative agents

Clinical Trial, and LEVANT 2 Continued Access Reg-

such as paclitaxel, a commonly used cancer chemo-

istry cohorts were used to identify predictors of

therapeutic agent. Although evidence documented

mortality and to assess the effect of additional study

markedly improved patency rates after treatment of

data on mortality outcomes. All analyses were done

femoropopliteal lesions with DES and DCBs compared

on an intention-to-treat basis.

AND ACRONYMS
CI = conﬁdence interval
DCB = drug-coated balloon
DES = drug-eluting stent(s)

disease

PTA = percutaneous
transluminal angioplasty

SAE = serious adverse event

ower

extremity

peripheral

with PTA (5–8), a recent systematic review and metaanalysis by Katsanos et al. (9) identiﬁed an increased
mortality signal associated with the use of paclitaxel
devices for femoropopliteal PAD.

INTERVENTIONAL TECHNIQUE. The Lutonix DCB is

intended to treat de novo or restenotic lesions within
the superﬁcial femoral or popliteal arteries. The DCB
is mounted on a 0.035-inch over-the-wire catheter

SEE PAGE 2525

with a proximal manifold. The surface concentration

The present review was undertaken to assess mortality after DCB treatment of femoropopliteal disease,
using independent patient-level data from the Lutonix
clinical program. The availability of independent
patient-level data from the Lutonix clinical program
allowed a granularity of analysis not possible with
research-derived data from meta-analyses.

of paclitaxel is 2 m g/mm2 , and the dose of paclitaxel
delivered was calculated by multiplying the surface
concentration by the surface area of the balloon that
comes in contact with the vessel. The instructions for
use recommend vessel preparation of the target
lesion using pre-dilation with an uncoated angioplasty balloon. A minimum inﬂation time of 120 s is
recommended for the Lutonix DCB.

METHODS

STUDY ENDPOINTS. All deaths were originally adju-

dicated by a blinded, independent, clinical events
DATA

SOURCES. The

randomized

analyses comprised the 3

controlled

trials

in

the

Lutonix

committee composed of varied specialists. As part of
the current meta-analysis, causes of death in the
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T A B L E 1 Global Lutonix Femoropopliteal Clinical Program

LEVANT 1

Drug per mm2

ClinicalTrials.gov
Identiﬁer

Enrollment Start

Study Design

Subjects Included
(DCB Angioplasty/PTA)

Geography

Follow-Up
(Months)

2

NCT00930813

June 2009

RCT

101 (49/52)

Europe

24

LEVANT 2 pivotal with roll-in DCB

2

NCT01412541

July 2011

RCT

532 (316/160)*

United States

60

LEVANT 2 (Continued
Access Registry)

2

NCT01628159

February 2013

Single arm

657

United States, Europe

60

LEVANT Japan Clinical Trial

2

NCT01816412

March 2013

RCT

109 (71/38)

Japan

24

SAFE-DCB U.S. registry

2

NCT02424383

April 2015

Single arm

1,005

United States

36

Lutonix Global SFA Registry

2

NCT01864278

December 2012

Single arm

Total

691

Europe

24

3,095 (2,845/250)

Europe, United States,
Japan

24–60

*There were 56 roll-in subjects treated with DCBs.
DCB ¼ drug-coated balloon; LEVANT 1 ¼ The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis; LEVANT 2 ¼ Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty
for the Treatment of Femoropopliteal Arteries; PTA ¼ percutaneous transluminal angioplasty; RCT ¼ randomized controlled trial; SAFE-DCB ¼ Real-World Registry Assessing the Clinical Use of the Lutonix
035 Drug Coated Balloon Catheter; SFA ¼ superﬁcial femoral artery.

LEVANT 1 and LEVANT 2 trials were readjudicated by

basis of known complications associated with the

an independent ad hoc adjudication committee

drug and a full review of all reported adverse events

comprising vascular surgeons, interventional radiol-

between enrollment and death, allowing ﬂexibility

ogists, and oncologists with systemic paclitaxel

for adjudicators to assign paclitaxel relatedness for

chemotherapy knowledge. Deaths in the LEVANT

mechanisms yet undescribed for paclitaxel. The

Japan Clinical Trial were not readjudicated, because

deaths were also classiﬁed by the Medical Dictionary

of unavailability of original source documents and

for Regulatory Activities version 2.10 (MedDRA

translations. A 2 þ 1 adjudication model and an elec-

MSSO,

tronic adjudication system (Syncrony, Syntactx, New

classiﬁcations.

McLean,

Virginia)

using

system

organ

York, New York) was used. In a 2 þ 1 adjudication
model, an interventionalist and an oncologist blinded

STATISTICAL ANALYSIS. To create commonality of

to treatment, DCB angioplasty or PTA, separately

variables, the datasets from individual trials were

adjudicated the elements of each events. If any

combined into analytic databases after mapping the

element of an adjudication was discordant between

variables using R version 3.5.2 (R Project for Statisti-

the 2 adjudicators, the discordant elements were

cal Computing, Vienna Austria). Statistical analyses

submitted to a tiebreaking adjudicator, who was al-

were performed using SAS version 9.4 (SAS Institute,

ways an oncologist.

Cary, North Carolina) and Stata/IC version 15.1

Deaths in the LEVANT 1 and LEVANT 2 trials were

(StataCorp, College Station, Texas). All analyses were

classiﬁed by their relationship to the device, pro-

performed by an independent clinical research orga-

cedure, and paclitaxel. They were also categorized as

nization (Syntactx).

cardiovascular or noncardiovascular. Cardiovascular

Comparisons of categorical data were done using

deaths were further subcategorized according to eti-

the Fisher exact test. Comparisons of continuous

ology, namely, acute myocardial infarction, sudden

variables were performed using Student’s t-test.

cardiac death, heart failure, stroke, cardiovascular

Freedom from all-cause mortality was estimated for

procedures, cardiovascular hemorrhage, or other

each trial using Kaplan-Meier methodology. Differ-

cardiovascular causes, using the guidelines estab-

ences were tested using the log-rank test.

lished by Hicks et al. (10). Noncardiovascular deaths

The Cox proportional hazards model was used to

were subcategorized and included pulmonary, renal,

predict survival up to 5 years. Patients were censored

gastrointestinal, hepatobiliary, pancreatic, infectious

at the time of death, at the date of last contact, or at 5

or inﬂammatory, hemorrhagic, procedural, trauma,

years, whichever came ﬁrst. A time-dependent co-

suicide, drug reaction (prescription and nonpre-

variate was created when a post-index procedure

scription), neurological (excluding cardiovascular

reintervention was performed on the femoropopliteal

neurological deaths), malignancy, and other non-

vessels of either leg, subcategorized by whether the

cardiovascular deaths. If the adjudicator could not

reintervention was with a paclitaxel-containing de-

determine if a death was cardiovascular or non-

vice. Models exploring the time-dependent relation-

cardiovascular, the death was classiﬁed as undeter-

ship of reinterventions included treatment arm

mined. Paclitaxel relatedness was adjudicated on the

(DCB angioplasty vs. PTA) as a baseline covariate. Cox
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T A B L E 2 Baseline and Demographic Characteristics of Patients in the Randomized Trials

LEVANT 1 RCT
DCB Angioplasty
(n ¼ 49)

DCB Angioplasty
(n ¼ 316)

LEVANT 2 CAR

PTA
(n ¼ 160)

DCB Angioplasty
(n ¼ 657)

LEVANT Japan Clinical Trial
DCB Angioplasty
(n ¼ 71)

PTA
(n ¼ 38)

66.7  8.4
69.9  9.6
p ¼ 0.073

67.6  10.0
68.8  9.0
p ¼ 0.197

68.5  9.6

72.5  9.8
78.2  8.1
p ¼ 0.002

69.4 (34/49)
57.7 (30/52)
p ¼ 0.302

61.1 (193/316)
66.9 (107/160)
p ¼ 0.229

63.8 (419/657)

63.4 (45/71)
68.4 (26/38)
p ¼ 0.676

Age, yrs
Male

LEVANT 2 RCT
PTA
(n ¼ 52)

Medical history
Arrhythmia

16.3 (8/49)

17.3 (9/52)

10.4 (33/316)

p > 0.999

14.4 (23/160)

11.7 (77/657)

p ¼ 0.229

8.5 (6/71)

10.5 (4/38)

p ¼ 0.737

Hypertension

35.9 (47/49)
86.5 (45/52)
p ¼ 0.162

89.2 (282/316)
87.5 (140/160)
p ¼ 0.647

88.0 (578/657)

84.5 (60/71)
92.1 (35/38)
p ¼ 0.371

Dyslipidemia

59.2 (29/49)

89.6 (283/316)

83.7 (550/657)

66.2 (47/71)

69.2 (36/52)

p ¼ 0.308

86.3 (138/160)

p ¼ 0.291

68.4 (26/38)

p > 0.999

Myocardial infarction

15.8 (3/19)
47.8 (11/23)
p ¼ 0.048

40.1 (63/157)
35.9 (28/78)
p ¼ 0.571

44.7 (143/320)

32.3 (10/31)
35.7 (5/14)
p > 0.999

Angina

10.5 (2/19)

21.0 (33/157)

28.4 (91/320)

61.3 (19/31)

Congestive heart failure
Renal failure

13.0 (3/23)

Diabetes

85.7 (12/14)

p ¼ 0.864

8.2 (4/49)
7.7 (4/52)
p > 0.999

5.7 (18/316)
3.1 (5/160)
p ¼ 0.263

7.0 (46/657)

4.2 (3/71)
15.8 (6/38)
p ¼ 0.063

3.5 (11/316)

8.8 (58/657)

7.0 (5/71)

20.4 (10/49)

CVA

19.2 (15/78)

p > 0.999

32.7 (17/52)

p ¼ 0.165

4.4 (7/160)

p ¼ 0.184

p ¼ 0.619

10.2 (5/49)
9.6 (5/52)
p > 0.999

11.4 (36/316)
11.3 (18/160)
p > 0.999

44.9 (22/49)

50.0 (26/52)

43.4 (137/316)

p ¼ 0.691

5.3 (2/38)

p > 0.999

41.9 (67/160)

10.5 (69/657)

18.3 (13/71)
23.7 (9/38)
p ¼ 0.617

36.7 (241/657)

46.5 (33/71)

47.4 (18/38)

p > 0.999

p ¼ 0.770

Prior revascularization*

65.3 (32/49)
53.9 (28/52)
p ¼ 0.311

66.1 (209/316)
69.1 (101/160)
p ¼ 0.542

62.7 (412/657)

47.9 (34/71)
50.0 (19/38)
p ¼ 0.844

Statins

73.5 (36/49)

77.2 (244/316)

73.5 (483/657)

53.5 (38/71)

67.3 (35/52)

p ¼ 0.522

78.8 (126/160)

p ¼ 0.728

55.3 (21/38)

p > 0.999

Smoking
Current

30.6 (15/49)
38.5 (20/52)
p ¼ 0.531

Previous

36.7 (18/49)

30.8 (16/52)

35.1 (111/316)
33.8 (54/160)
p ¼ 0.839
44.0 (139/316)

p ¼ 0.536
Never

32.7 (16/49)
30.8 (16/52)
p > 0.999

48.8 (78/160)

35.8 (235/657)

21.1 (15/71)
26.3 (10/38)
p ¼ 0.634

46.3 (304/657)

53.5 (38/71)

p ¼ 0.332

42.1 (16/38)

p ¼ 0.316

20.9 (66/316)
17.5 (28/160)
p ¼ 0.397

18.0 (118/657)

23.4 (18/71)
31.6 (12/38)
p ¼ 0.507

Values are mean  SD or % (n/n). *Refers to peripheral revascularization.
CAR ¼ Continued Access Registry; CVA ¼ cerebrovascular accident; other abbreviations as in Table 1.

proportional hazards modeling was used to identify

and PTA patients were current or former smokers.

predictors of time to adverse events, time to serious

The average target lesion length was 62.1  41.6 mm

adverse events (SAEs), and time to death.

in the DCB group and 62.3  40.9 mm in the PTA
group (Table 3). Most target lesions were de novo

RESULTS

(DCB, 87.7%; PTA, 91.9%), and calciﬁcation was reported in 59.2% of DCB patients and 58.1% of PTA

DEMOGRAPHIC AND BASELINE CHARACTERISTICS.

patients. The most common baseline Rutherford

The demographic and baseline characteristics were

category was 3 (DCB, 62.7%; PTA, 57.5%), and the

comparable in patients treated with DCB angioplasty

average ankle brachial index was 0.7  0.2 in both

and PTA in the LEVANT trials (Table 2). Patients in the

groups. Patients in the DCB arm received a mean

LEVANT 2 study were largely men (DCB angioplasty,

paclitaxel dose of 3.6  1.9 mg at the index procedure.

61.1%; PTA, 66.9%), and the most common comorand

SURVIVAL ANALYSES. A survival analysis of LEVANT

myocardial infarction. Approximately 80% of DCB

2 revealed a numerically higher 5-year survival in the

bidities

were

hypertension,

dyslipidemia,
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T A B L E 3 Target Lesion Characteristics and Paclitaxel Dose in the Randomized Trials

LEVANT 1 RCT

Rutherford category
2

LEVANT 2 RCT

LEVANT 2 CAR

DCB Angioplasty

PTA

DCB Angioplasty

PTA

0.0 (0/49)

0.0 (0/52)

29.4 (93/316)

34.4 (55/160)

LEVANT Japan Clinical Trial

DCB Angioplasty DCB Angioplasty

36.5 (240/657)

59.2 (42/71)

p ¼ 0.295
3

22.5 (11/49)
21.2 (11/52)
p > 0.999

4

71.4 (35/49)

71.2 (37/52)

7.9 (25/316)

55.3 (21/38)

p ¼ 0.839

62.7 (198/316) 57.5 (92/160)
p ¼ 0.276

p > 0.999

PTA

8.1 (13/160)

57.7 (379/657)
5.8 (38/657)

40.9 (29/71)
42.1 (16/38)
p > 0.999
0.0 (0/71)

p > 0.999

2.6 (1/38)

p ¼ 0.349

5

2.0 (1/49)
3.9 (2/52)
p > 0.999

0.0 (0/316)

0.0 (0/160)

0.0 (0/657)

0.0 (0/71)

0.0 (0/38)

6

4.1 (2/49)

0.0 (0/316)

0.0 (0/160)

0.0 (0/657)

0.0 (0/71)

0.0 (0/38)

3.9 (2/52)

p > 0.999
Lesion
De novo

89.4 (42/47) 88.5 (46/52)
p > 0.999

Recurrent

10.6 (5/47)

11.5 (6/52)

87.7 (277/316) 91.9 (147/160) 90.6 (595/657)
p ¼ 0.213
12.3 (39/316)

p > 0.999
Calciﬁcation (% of patients)

8.1 (13/160)

9.4 (62/657)

95.8 (68/71) 94.7 (36/38)
p > 0.999
4.2 (3/71)

p ¼ 0.213

NA

59.2 (187/316)

58.1 (93/160)

66.2 (435/657)

46.5 (33/71)

p ¼ 0.844
0.8  0.2

Ankle-brachial index

0.8  0.3

0.7  0.2

p ¼ 0.374
Total lesion length, mm

88.1  36.8

86.2  38.1

62.1  41.6

Reference vessel diameter, mm

5.0  0.6

Maximum diameter stenosis, %

89.0  9.8

5.2  0.6

4.8  0.8

90.1  11.1

2.8  0.7

0.7  0.3

0.7  0.1

80.3  14.8

62.3  40.9

53.9  40.7

67.7  43.5

3.6  1.9

55.3  51.0

p ¼ 0.208

4.8  0.8

4.8  0.8

4.9  0.7

4.7  0.7

p ¼ 0.397

80.8  14.9

82.2  13.8

80.9  14.8

p ¼ 0.709
NA

0.7  0.1

p ¼ 0.908

p ¼ 0.993

p ¼ 0.607
Mean paclitaxel dose, mg

0.7  0.2

p ¼ 0.949

p ¼ 0.096

60.5 (23/38)

p ¼ 0.228

p ¼ 0.825

p ¼ 0.7980

5.3 (2/38)

p > 0.999

78.3  13.2

p ¼ 0.357
NA

3.5  1.8

2.0  0.9

NA

Values are mean  SD or % (n/N).
NA ¼ not applicable; other abbreviations as in Tables 1 and 2.

PTA arm (87.7  2.7%) compared with the DCB arm

When the HR was adjusted for post-procedural

(80.8  2.3%), but the difference did not attain sta-

reinterventions as a time-dependent covariate, the

tistical signiﬁcance (p ¼ 0.084). The 2-year hazard

resulting 1-year HR was 0.99 (95% CI: 0.30 to 3.28),

ratio (HR) after DCB angioplasty was 0.99 (95% con-

and the 5-year HR was 1.64 (95% CI: 0.95 to 2.82).

ﬁdence interval [CI]: 0.25 to 3.95) in LEVANT 1, 1.40

The 5-year HR was unchanged when adjusted for

(95% CI: 0.62 to 3.14) in LEVANT 2, and 0.32 (95% CI:

post-procedural

0.05 to 1.92) in the LEVANT Japan Clinical Trial. The

containing devices as a time-dependent covariate

reinterventions

with

paclitaxel-

LEVANT 2 randomized trial HR for all-cause mortal-

(at 5 years, HR: 1.65; 95% CI: 0.95 to 2.84).

ity increased from 1.13 (95% CI: 0.35 to 3.68;

CLUSTERING OF DEATH AND ADVERSE EVENTS.

p ¼ 0.834) at 1 year to 1.60 (95% CI: 0.94 to 2.72;

The causes of death are summarized in Table 4, as

p ¼ 0.084) at 5 years. The HR was 1.25 (95% CI: 0.765

adjudicated by the independent committee. Among

to 2.045; p ¼ 0.3715) at 5 years in the LEVANT 2

the 173 deaths in LEVANT 1 and LEVANT 2 (including

combined randomized and Continued Access Regis-

the Continued Access Registry patients), 151 occurred

try DCB cohorts versus PTA. Survival differences

in DCB patients (14.0%) and 22 in PTA patients

between DCB angioplasty and PTA diminished as

(10.4%). Among these, none were adjudicated as

data from the trials were aggregated. The HR was 1.01

related to paclitaxel.

(95% CI: 0.68 to 1.52; p ¼ 0.95) through 5 years

There was no clustering of deaths in any category;

(including all visits) in the aggregated analysis

differences in the proportion of deaths of any 1 cate-

dataset of LEVANT 1, LEVANT 2, and the LEVANT

gory within the DCB or the PTA cohorts were not

Japan Clinical Trial (Central Illustration). The median

statistically signiﬁcant. Patients died of cardiovascu-

follow-up duration for the 3 studies was 1,779 days

lar causes in 5.1% (55 of 1,078) and 3.8% (8 of 212) of

(interquartile range: 892 to 1,847 days).

the DCB and PTA groups, respectively (p ¼ 0.489).
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C E N T R A L IL L U ST R A T I O N Lutonix Drug-Coated Balloon and Study Outcome

A

DRUG

LUTONIX® 035 DCB drug dose
of paclitaxel is 2 μg/mm2

+ CARRIER
Polysorbate and sorbitol

= COATING
Facilitates therapeutic drug
retention and release of
drug at the treatment site

B
100

Percent

2520

86.1%

80
84.5%

60
0
0
PTA
DCB

365

Number at Risk
250
224
1,093
1,024

760
200
939

1,095

1,460

1,825

138
812

128
760

70
363

Ouriel, K. et al. J Am Coll Cardiol Intv. 2019;12(24):2515–24.

(A) Components of the Lutonix drug-coated balloon (DCB). The Lutonix balloon, indicated for the treatment of peripheral artery disease, is
coated with paclitaxel to prevent vessel restenosis. (B) Survival in LEVANT 1 (The Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropopliteal Restenosis), LEVANT 2 (Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal
Arteries), and LEVANT Japan Clinical Trial. Aggregated survival outcomes from the 3 trials show comparable 5-year survival rates in the
percutaneous transluminal angioplasty (PTA) and DCB angioplasty groups.
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Noncardiovascular deaths occurred in 7.3% (79 of
1,078) and 5.2% (11 of 212) of the DCB and PTA groups

T A B L E 4 Adjudicated Causes of Death

(p ¼ 0.304). There was no difference in the proportion
of deaths of undetermined cause in the 2 groups, 1.6%
(17 of 1,078) in the DCB group versus 1.4% (3 of 212) in
the PTA group (p > 0.999).
Cardiovascular deaths were balanced in the DCB
and PTA groups. The most common subtypes were
heart failure, occurring in 1.9% (21 of 1,078) and 1.4%
(3 of 212) of the DCB and PTA groups, respectively
(p ¼ 0.784), followed by acute myocardial infarction,
occurring in 1.3% (14 of 1,078) of the DCB group and
0.9% (2 of 212) of the PTA group (p > 0.999). Noncardiovascular deaths were also balanced in the 2
groups.

Among

subtypes

of

noncardiovascular

deaths, neoplasm predominated; 4.5% (48 of 1,078) in
the DCB group versus 3.3% (7 of 212) in the PTA group
(p ¼ 0.577). Among neoplastic deaths, lung cancer
was most common (1.5% [16 of 1,078] in the DCB
group and 1.4% [3 of 212] in the PTA group;
p > 0.999), followed by gastrointestinal malignancies
(0.7% [8 of 1,078] in the DCB group and 1.9% [4 of 212]
in the PTA group; p ¼ 0.119).
We analyzed the frequency of SAEs in the LEVANT 2
randomized cohorts as precursors of death, because
new-onset events may not culminate in mortality over

DCB Angioplasty

PTA

p Value

CV deaths
Heart failure
Acute MI
CV hemorrhage
Stroke
Sudden cardiac death
Other

5.1 (55/1,078)
1.9 (21/1,078)
1.3 (14/1,078)
0.1 (1/1,078)
0.6 (7/1,078)
0.6 (7/1,078)
0.5 (5/1,078)

3.8 (8/212)
1.4 (3/212)
0.9 (2/212)
0.0 (0/212)
0.5 (1/212)
0.5 (1/212)
0.5 (1/212)

0.489
0.784
>0.999
>0.999
>0.999
>0.999
>0.999

Non-CV deaths
Neoplasm
Blood-based
Brain
Gastrointestinal
Lung
Pancreatic
Other
Undetermined neoplasm
Non-neoplasm
Hepatobiliary
Infection
Pulmonary
Renal
Suicide
Trauma
Inﬂammatory

7.3 (79/1,078)
4.5 (48/1,078)
0.1 (1/1,078)
0.2 (2/1,078)
0.7 (8/1,078)
1.5 (16/1,078)
0.1 (1/1,078)
1.2 (13/1,078)
0.2 (2/1,078)
2.9 (31/1,078)
0.1 (1/1,078)
1.4 (15/1,078)
0.7 (8/1,078)
0.2 (2/1,078)
0.2 (2/1,078)
0.2 (2/1,078)
0.1 (1/1,078)

5.2 (11/212)
3.3 (7/212)
0.0 (0/212)
0.0 (0/212)
1.9 (4/212)
1.4 (3/212)
0.0 (0/212)
0.0 (0/212)
0.0 (0/212)
1.9 (4/212)
0.0 (0/212)
1.4 (3/212)
0.0 (0/212)
0.5 (1/212)
0.0 (0/212)
0.0 (0/212)
0.0 (0/212)

0.304
0.577
>0.999
>0.999
0.119
>0.999
>0.999
0.143
>0.999
0.642
>0.999
>0.999
0.367
0.417
>0.999
>0.999
>0.999

1.6 (17/1,078)

1.4 (3/212)

>0.999

14.0 (151/1,078)

10.4 (22/212)

0.186

Undetermined deaths
All deaths
Values are % (n/N).

CV ¼ cardiovascular; MI ¼ myocardial infarction; other abbreviations as in Table 1.

the follow-up observation period. Overall, there were
530 SAEs in the 316 DCB patients (1.7 per patient) and
284 in the 160 PTA patients (1.8 per patient). SAEs were
balanced in the 2 treatment arms (Table 5). SAEs of any
type occurred in 30.4% (96 of 316) of DCB patients
versus 27.5% (44 of 160) of PTA patients (p ¼ 0.525).

dose-response relationship was identiﬁed using the
Cox proportional hazards model when adjusted
for the predictors of mortality identiﬁed earlier
(p $ 0.05).

Cardiovascular SAEs occurred in 18.0% (57 of 316)
versus 18.1% (29 of 160) patients in the DCB and PTA

T A B L E 5 Rates of Adverse Events Between Groups

treatment arms, respectively (p > 0.999). There were
no signiﬁcant between-group differences in the rates

DCB Angioplasty

PTA

p Value

Serious adverse events

of other types of SAEs, with 2 exceptions: gastroin-

Cardiovascular

18.0 (57/316)

18.1 (29/160)

>0.999

testinal SAEs occurred in numerically fewer patients in

Bleeding

4.1 (13/316)

3.1 (5/160)

0.800

the DCB group (6.6% [21 of 316] vs. 12.5% [20 of 160];

Infection

8.9 (28/316)

7.5 (12/160)

0.727

p ¼ 0.038), as did peripheral vascular SAEs (32.0% [101

Malignancy

6.3 (20/316)

4.4 (7/160)

0.530

of 316] vs. 40.6% [65 of 160]; p ¼ 0.067).

Arrythmia

2.8 (9/316)

5.0 (8/160)

0.295

Pulmonary

10.4 (33/316)

7.5 (12/160)

0.325

Orthopedic

8.9 (28/316)

10.6 (17/160)

0.619

SUBSET ANALYSES. Using the combined randomized

and Continued Access Registry cohorts of the

Gastrointestinal

LEVANT 2 trial, the results of a stepwise Cox

Peripheral Vascular

proportional hazards model for mortality rate in

Neurological

LEVANT 2 identiﬁed the following covariates predic-

Any type

tive of mortality: age, left-sided target limb, Ruth-

Adverse events*

erford category, angiotensin II receptor blockers at

Cardiovascular
Bleeding
Infection
Malignancy
Any type

discharge, prior treatment of the target lesion, anticoagulant agents at discharge, arrhythmia at baseline,
and diabetes (Table 6). Dose was not a signiﬁcant
covariate in the model.
The effect of dose was studied further using quar-

6.6 (21/316)

12.5 (20/160)

0.038

32.0 (101/316)

40.6 (65/160)

0.067

7.9 (25/316)

5.6 (9/160)

0.452

30.4 (96/316)

27.5 (44/160)

0.525

45.6 (144/316)
13.9 (44/316)
32.0 (101/316)
12.3 (39/316)
62.7 (198/316)

50.0 (80/160)
12.5 (20/160)
30.6 (49/160)
8.8 (14/160)
66.9 (107/160)

0.383
0.776
0.835
0.282
0.419

Values are % (n/N). *Includes serious adverse events.
Abbreviations as in Table 1.

tiles corresponding to increasing doses. No signiﬁcant
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interventional devices for femoropopliteal angio-

T A B L E 6 Multivariate Analysis of Mortality

plasty. Published studies met their pre-determined

Hazard Ratio

LCL

UCL

p Value

primary safety endpoints and showed a 40% reduc-

Age (per yr)

1.03

1.02

1.05

<0.001

tion in target lesion reinterventions after DES and

Left-sided target limb

1.55

1.12

2.15

0.009

DCB treatment compared with uncoated PTA, a

Rutherford category

1.41

1.08

1.84

0.012

ﬁnding that persisted through 5-year follow-up (8,11).

ARB at discharge

0.58

0.37

0.89

0.013

A study of Medicare beneﬁciaries also found no dif-

Prior treatment to target lesion

1.67

1.08

2.60

0.022

ferences in mortality in patients with PAD treated

Anticoagulant agents at discharge

2.13

1.10

4.12

0.025

with DES or bare-metal stents (4).

Arrhythmia at baseline

1.65

1.05

2.61

0.031

The systematic review and meta-analysis of Kat-

Diabetes

1.18

1.00

1.40

0.047

sanos et al. (9) found an almost 2-fold increase in the
relative risk for all-cause mortality after treatment

Stepwise Cox proportional hazards stepwise regression, propensity adjusted using stratiﬁcation,
LEVANT 2 randomized arms and Continued Access Registry cohort.
ARB ¼ angiotensin II receptor blocker; LCL ¼ 95% lower conﬁdence limit; UCL ¼ 95% upper
conﬁdence limit.

with paclitaxel-containing devices compared with
uncoated PTA for femoropopliteal PAD. It is important to note that none of the studies included in the
review by Katsanos et al. (9) were designed to assess

The effect of reintervention on survival was eval-

or powered to detect a mortality signal, especially in

uated in the LEVANT 2 randomized trial. DCB patients

the later years of follow-up (12). As such, the observa-

who

tions should be treated as hypothesis generating only.

underwent

reintervention,

either

with

or

without a paclitaxel device, had a higher 5-year sur-

The numeric association between paclitaxel and

vival rate (87.8  4.3%) than DCB patients without

mortality, although demonstrated in several random-

reintervention (79.3  2.7%). Similarly, the 5-year

ized trials, does not conﬁrm causality (6–8,13). In most

survival rate for PTA patients with reintervention,

randomized trials, the treatment groups are balanced

paclitaxel or not, was higher than the rate for PTA

at the onset. Demographic characteristics, baseline

patients

reintervention

comorbidities, and the anatomic characteristics of the

(93.5  4.4% vs. 86.8  3.2%). Reintervention with a

target lesions are similar in the 2 treatment arms. The

paclitaxel-coated or paclitaxel-eluting device versus

composition of the analytic dataset may change over

no reintervention was found to increase survival in

time, however, as patients return for follow-up in a

the DCB (85.8  5.4% vs. 80.0  2.6%) and PTA

differential fashion between the 2 treatment arms.

(92.0  5.4% vs. 86.8  3.1%) arms.

Originally balanced groups may become unbalanced

who

did

not

undergo

When stepwise Cox proportional hazards modeling

with respect to comorbidities. Unblinded trials are

was performed with treatment (DCB angioplasty or

especially prone to post-treatment population differ-

PTA) as a covariate, various factors were identiﬁed

ences, as are trials in which the randomized treatment

that were predictive of all SAEs and of speciﬁc SAE

itself produces differences in patient and physician

types. Treatment with DCB angioplasty or PTA,

behavior. For instance, patient follow-up compliance

however, was not predictive of SAEs in general or for

may be different when 1 treatment is associated with

any speciﬁc SAE type.

marked improvement in effectiveness; patients who
have improvement in symptoms may be less likely to

DISCUSSION

continue with a protocol-speciﬁed follow-up visit
schedule. By contrast, patients who have failed effec-

Patient-level data from the Lutonix femoropopliteal

tiveness, for example, those with target lesion reste-

clinical program refute the observations of increased

nosis, may be treated more aggressively for their

mortality after DCB angioplasty treatment. Although

systemic atherosclerotic disease with more antiplate-

numerically increased mortality risk was observed in

let and antihyperlipidemic medications or other

the LEVANT 2 randomized trial, the mortality signal

medical therapies.

was not statistically signiﬁcant, paclitaxel did not

Reintervention itself was protective against mor-

appear to be a predictor of mortality in multivariate

tality. Irrespective of whether patients were in the

analyses, the relationship between dose and risk was

DCB or the PTA randomized treatment arm, they were

not evident after adjustment for predictors of mortal-

less likely to die if they underwent reintervention.

ity from the multivariate analysis, and the signal was

The same ﬁnding was noted with paclitaxel reinter-

not present in the other LEVANT randomized trials.

ventions; reintervention with paclitaxel-containing

regulatory

devices was protective against mortality whether a

approval of DCBs and stents uniformly conﬁrmed the

Randomized

controlled

trials

for

patient was in the DCB or PTA randomized treatment

safety and effectiveness of paclitaxel-containing

arm.
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These observations raise the specter of whether the
mortality signal identiﬁed by Katsanos et al. (9) and
others is from causation, with paclitaxel causing death
due to a yet undetermined mechanism, or whether the
ﬁnding is from a noncausal association with a postrandomization effect. The criteria of Bradford Hill
were created more than 50 years ago as a paradigm to
identify when an observed association has underlying
causation between treatment and outcome (14). Hill
proposed 9 aspects of association that have become
fundamental tenets of causal inference. The Hill
criteria, as applied to the association between paclitaxel femoropopliteal interventions and mortality,
begin with the strength of association. The greater the
strength, the more likely an association is causal. The
Lutonix data demonstrated a weak association between paclitaxel and death; the HRs overlapped 1 in all
studies. The second criterion, consistency, was also
not upheld. Among the studies, only LEVANT 2 had a
mortality signal, and other studies had a numerically
lower risk for death with DCB angioplasty. The Hill
criterion of speciﬁcity (exposure causes the event
through 1 speciﬁc pathway) was not evident. There
was no clustering of adverse event types or causes of
SAEs or deaths, as would be expected if paclitaxel observations were causative through 1 pathway, for
example, through a cardiovascular, neoplastic, or infectious mechanism. Temporality, epidemiologically
the most essential of the criteria, was not evident in the

mortality rate in its DCB arm, this association did not
satisfy any of the criteria for causation.
STUDY LIMITATIONS. The analyses were limited by

the relatively small sizes of the randomized trials and
the small numbers of patients in the PTA arms, with a
large imbalance in the protocol-deﬁned ratio of DCB
to PTA patients. Baseline covariates and concomitant
medications were limited to those that were anticipated to be important for trials with clinically driven
target lesion revascularization as the primary effectiveness endpoint. Dose-response relationships may
be stochastic rather than deterministic and, as such,
would not be detected with the present analysis. Loss
to follow-up may not have occurred at random and
was unbalanced between the 2 treatment arms. The
studies were neither powered for mortality nor able
to

accurately

assess

potential

links

between

concomitant medications and paclitaxel treatment.
The causes of death were not always evident from the
original medical records. As well, when aggregating
trials or cohorts, no adjustments were made for differences in population or treatment effect. Therefore,
there may be measured or unmeasured covariates
that differ among the trials or cohorts that could
affect the ﬁndings. Last, the ﬁndings of this metaanalysis may not be generalizable to other commercially available DCBs, as each DCB differs in general
properties, paclitaxel dose, and excipient.

Lutonix analysis. Events occurred years after paclitaxel left the body. The mortality signal becomes

CONCLUSIONS

evident several years after paclitaxel is cleared from
the body, but preclinical studies document absence of

An analysis of individual patient-level data from the

paclitaxel in the bloodstream after several hours and

full LEVANT dataset (LEVANT 1, LEVANT 2, and the

clearance from the arterial wall and organs within a

LEVANT Japan Clinical Trial randomized trials as

few months. If an agent causes an event, there should

well as the LEVANT 2 Continued Access Registry)

be a dose-response relationship. Dose was not identi-

demonstrated no increase in mortality with the use

ﬁed as a predictor of either adverse events or of mor-

of DCBs. The studies were not powered to detect

tality

performed.

mortality differences, however, and a larger sample

Biological plausibility and coherence were enigmatic,

size with prospective assignment of mortality as an

at least with respect to the current body of knowledge

endpoint would be required to reach a deﬁnitive,

on paclitaxel’s known molecular mechanisms and its

more robust conclusion. Although a numeric in-

interaction with other drugs. Despite analyses of the

crease in mortality was observed in the LEVANT 2

Lutonix studies and those of others, no known mech-

DCB randomized treatment arm compared with the

anism of increased mortality with paclitaxel use has

PTA arm, the difference was not statistically signif-

been elucidated. Experimental manipulation, the

icant. The HR was closer to 1.0 as additional data

penultimate Hill criterion, is not relevant to DCB trials,

from the other trials were aggregated. The associa-

because the duration of exposure cannot be manipu-

tion between DCB and late mortality does not imply

lated to ascertain the effect of cessation of treatment

causality, and mortality differences may be better

on outcome. The last criterion, that of analogy, is also

explained by the differences in post-randomization

not relevant to paclitaxel studies, because there are

medical treatment in the 2 cohorts, DCB angio-

few other similar agents that have been studied in this

plasty and PTA. The identiﬁcation of factors pre-

clinical setting. In summary, although the LEVANT 2

dictive of mortality after treatment may be due to

randomized trial had a numerically higher 5-year

chance

in

the

multivariate

analyses

alone;

alternatively,

the

observed
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associations may arise from associations between
the identiﬁed predictor and other, unmeasured
covariates. The beneﬁcial effect of reinterventions
suggests a survival advantage related to more
frequent

patient-physician

encounters.

Further

analysis of existing datasets from clinical trials and

PERSPECTIVES
WHAT IS KNOWN? Following publication of a
meta-analysis that revealed increased mortality in
patients treated with paclitaxel coated balloons, the

real-world registries may elucidate these ﬁndings.

U.S. Food and Drug Administration held an advisory
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board meeting to evaluate paclitaxel as an approved

paclitaxel devices from 5 manufacturers.
WHAT IS NEW? This publication reports granular
data speciﬁc to the Bard Lutonix DCB.
WHAT IS NEXT? While these patient-level data will
help a reader evaluate the Lutonix product in clinical
practice, they will also form a basis for the design of
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